Covaxin (BBVI52), which has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is an investigational vaccine candidate product in the US. Bharat Biotech…
The trials will evaluate the nasal vaccine for both the primary dose schedule as well as the booster one, Bharat Biotech said. Intranasal vaccines are easier to administer in mass…
An intra-nasal vaccine would not only be simple to administer but also reduce the use of needles and syringes, among others. Bharat Biotech has received approval from the Drug Controller…
Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections. Bharat Biotech on Saturday said trials have indicated that its vaccine Covaxin is…
The Centre has also set guidelines for this vaccination drive and the SOP outlines types of vaccine that can be administered and the method of reserving slots. India is getting…
PM Modi in a surprise address to the nation on December 25 announced that cpvod-19 vaccination for children in the 15-18 age group will start from January 3. The World…
The decisions came amid rising Covid cases linked to the Omicron variant of the virus. Bharat Biotech’s Covaxin is likely to be the only COVID-19 vaccine available, for now, for…
Bharat Biotech’s nasal vaccine, BBV154, has already completed Phase-2 trials with Covaxin. The proposed Ph-3 trials will cover those who have been administered with any two doses of the Covid-19…
An intranasal vaccine as a booster dose would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission. Bharat Biotech has sought the Drug Controller…
Covaxin and help boost Vietnam’s national vaccination programme. Bharat Biotech and its local partner Dunc Minh have donated 200,000 doses of Covaxin to the Republic of Vietnam. The Covid-19 vaccine…